Literature DB >> 11907219

Kunjin virus replicon vaccine vectors induce protective CD8+ T-cell immunity.

Itaru Anraku1, Tracey J Harvey, Richard Linedale, Joy Gardner, David Harrich, Andreas Suhrbier, Alexander A Khromykh.   

Abstract

The ability of self-replicating RNA (replicon) vaccine vectors derived from the Australian flavivirus Kunjin (KUN) to induce protective alphabeta CD8+ T-cell responses was examined. KUN replicons encoding a model immunogen were delivered by three different vaccine modalities: (i) as naked RNA transcribed in vitro, (ii) as plasmid DNA constructed to allow in vivo transcription of replicon RNA by cellular RNA polymerase II (DNA based), and (iii) as replicon RNA encapsidated into virus-like particles. A single immunization with any of these KUN replicon vaccines induced CD8+ T-cell responses at levels comparable to those induced by recombinant vaccinia virus encoding the same immunogen. Immunization with only 0.1 microg of DNA-based KUN replicons elicited CD8+ T-cell responses similar to those seen after immunization with 100 microg of a conventional DNA vaccine. Naked RNA immunization with KUN replicons also protected mice against challenges with recombinant vaccinia virus and B16 tumor cells. These results demonstrate the value of KUN replicon vectors for inducing protective antiviral and anticancer CD8+ T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907219      PMCID: PMC136104          DOI: 10.1128/jvi.76.8.3791-3799.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

Review 1.  Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.

Authors:  A J Ramsay; S J Kent; R A Strugnell; A Suhrbier; S A Thomson; I A Ramshaw
Journal:  Immunol Rev       Date:  1999-10       Impact factor: 12.988

2.  Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus.

Authors:  L J Johnston; G M Halliday; N J King
Journal:  J Invest Dermatol       Date:  2000-03       Impact factor: 8.551

3.  cis- and trans-acting elements in flavivirus RNA replication.

Authors:  A A Khromykh; P L Sedlak; E G Westaway
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

4.  Effect of pre-existing cytotoxic T lymphocytes on therapeutic vaccines.

Authors:  M A Sherritt; J Gardner; S L Elliott; C Schmidt; D Purdie; G Deliyannis; W R Heath; A Suhrbier
Journal:  Eur J Immunol       Date:  2000-02       Impact factor: 5.532

5.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

6.  Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge.

Authors:  A Seth; I Ourmanov; J E Schmitz; M J Kuroda; M A Lifton; C E Nickerson; L Wyatt; M Carroll; B Moss; D Venzon; N L Letvin; V M Hirsch
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

7.  Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis.

Authors:  G H MacDonald; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Loss of dimerisation of the nonstructural protein NS1 of Kunjin virus delays viral replication and reduces virulence in mice, but still allows secretion of NS1.

Authors:  R A Hall; A A Khromykh; J M Mackenzie; J H Scherret; T I Khromykh; J S Mackenzie
Journal:  Virology       Date:  1999-11-10       Impact factor: 3.616

9.  Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine.

Authors:  M N Fleeton; P Liljeström; B J Sheahan; G J Atkins
Journal:  J Gen Virol       Date:  2000-03       Impact factor: 3.891

10.  Stable high-level expression of heterologous genes in vitro and in vivo by noncytopathic DNA-based Kunjin virus replicon vectors.

Authors:  A N Varnavski; P R Young; A A Khromykh
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

View more
  23 in total

1.  Mimicking live flavivirus immunization with a noninfectious RNA vaccine.

Authors:  Regina M Kofler; Judith H Aberle; Stephan W Aberle; Steven L Allison; Franz X Heinz; Christian W Mandl
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

2.  DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus.

Authors:  Roy A Hall; Debra J Nisbet; Kim B Pham; Alyssa T Pyke; Greg A Smith; Alexander A Khromykh
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-13       Impact factor: 11.205

3.  Humoral and cellular immune response to RNA immunization with flavivirus replicons derived from tick-borne encephalitis virus.

Authors:  Judith H Aberle; Stephan W Aberle; Regina M Kofler; Christian W Mandl
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  A totally synthetic vaccine of generic structure that targets Toll-like receptor 2 on dendritic cells and promotes antibody or cytotoxic T cell responses.

Authors:  David C Jackson; Yuk Fai Lau; Thuy Le; Andreas Suhrbier; Georgia Deliyannis; Christina Cheers; Corey Smith; Weiguang Zeng; Lorena E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-15       Impact factor: 11.205

Review 5.  Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion.

Authors:  Melanie A Samuel; Michael S Diamond
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 6.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 7.  A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs.

Authors:  Karl-Josef Kallen; Andreas Theß
Journal:  Ther Adv Vaccines       Date:  2014-01

8.  Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription.

Authors:  Wen Jun Liu; Hua Bo Chen; Xiang Ju Wang; Hester Huang; Alexander A Khromykh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Tetracycline-inducible packaging cell line for production of flavivirus replicon particles.

Authors:  Tracey J Harvey; Wen Jun Liu; Xiang Ju Wang; Richard Linedale; Michael Jacobs; Andrew Davidson; Thuy T T Le; Itaru Anraku; Andreas Suhrbier; Pei-Yong Shi; Alexander A Khromykh
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Long-term storage of DNA-free RNA for use in vaccine studies.

Authors:  Kathryn L Jones; Debbie Drane; Eric J Gowans
Journal:  Biotechniques       Date:  2007-11       Impact factor: 1.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.